• Explore /
  • Poster
  • / UNICAB: Cabozantinib in locally advanced or metastatic non‐clear cell renal cell carcinoma post immunotherapy or in those unsuitable for immunotherapy (ANZUP 1802).

UNICAB: Cabozantinib in locally advanced or metastatic non‐clear cell renal cell carcinoma post immunotherapy or in those unsuitable for immunotherapy (ANZUP 1802).

Abstract Poster

Authors

David Pook

David William Pook

Monash Cancer Centre, Clayton, Australia

David William Pook , Carole A. Harris , Emma Link , Jeffrey C. Goh , Francis Parnis , Howard Gurney , Ganessan Kichenadasse , Craig Underhill , Javier Torres , Felicia Roncolato , Andrisha Jade Inderjeeth , Ciara Conduit , Margaret Mary McJannett , Ian D. Davis , Craig Gedye

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2024 ASCO Genitourinary Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session C: Renal Cell Cancer; Adrenal, Penile, and Testicular Cancers

Track

Renal Cell Cancer,Adrenal Cancer,Penile Cancer,Testicular Cancer

Sub Track

Therapeutics

Clinical Trial Registration Number

NCT03685448

Citation

J Clin Oncol 42, 2024 (suppl 4; abstr 428)

DOI

10.1200/JCO.2024.42.4_suppl.428

Abstract #

428

Poster Bd #

H10

Abstract Disclosures

Similar Posters

First Author: Elena Verzoni

First Author: Carolyn Moloney

First Author: Bradley Alexander McGregor

First Author: Georg Bartsch